Συγγραφείς:
Jalink, M.
Berentsen, S.
Castillo, J.J.
Treon, S.P.
Cruijsen, M.
Fattizzo, B.
Cassin, R.
Fotiou, D.
Kastritis, E.
De Haas, M.
Oosten, L.E.M.
Frederiksen, H.
Patriarca, A.
D'Sa, S.
Vos, J.M.I.
Λέξεις-κλειδιά:
bendamustine; bortezomib; Bruton tyrosine kinase inhibitor; chlorambucil; cyclophosphamide; dexamethasone; fludarabine; granulocyte colony stimulating factor; hemoglobin; ibrutinib; immunoglobulin; lactate dehydrogenase; mycophenolate mofetil; myeloid differentiation factor 88; obinutuzumab; rituximab; steroid; adenine; BTK protein, human; ibrutinib; piperidine derivative; protein kinase inhibitor, acrocyanosis; aged; autoimmune hemolytic anemia; blood level; chronic lymphatic leukemia; clinical article; clinical study; contusion; diarrhea; drug efficacy; drug substitution; drug withdrawal; female; follow up; gene mutation; hemoglobin blood level; hemolytic anemia; human; information processing; Letter; lymphocytic lymphoma; male; medical parameters; multiple cycle treatment; neutropenia; plasmapheresis; questionnaire; rash; retrospective study; Waldenstroem macroglobulinemia; autoimmune hemolytic anemia; complication; cyanosis; middle aged; very elderly, Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Cyanosis; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Retrospective Studies
